ロード中...
The HRD decision--which PARP inhibitor to use for whom and when
Rucaparib, a polyADPribose polymerase (PARP) inhibitor, was approved recently for use in women with high grade serous ovarian cancer (HGSOC). It is now one of 3 approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome.
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5712252/ https://ncbi.nlm.nih.gov/pubmed/28974545 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2186 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|